It’s been a few years since Brexit and pharmaceutical companies have been adapting their therapy development plans as regulatory guidelines for different regions get updated. Health technology assessments or HTAs remain one area where the divergence of reimbursement frameworks in the UK and European Union is expected to impact how and when new therapies become available in those regions.

In this month’s issue, we take a look at how market access following an evolving process to conduct HTAs is expected to change in the near future in the UK.

Also, in this issue, we tackle the sparse research landscape for treatments for prion diseases and whether all generic manufacturers can pivot to producing specialty and complex generics.

Do catch the guest columns on digital health in pharma, and how collaborative research has led to new ways to study long Covid.

All this, and the latest pharma industry news, comment, data, and analysis from GlobalData.

Manasi Vaidya, editor

Go to article: Home | Technology transformationGo to article: In this issueGo to article: ContentsGo to article: SHL Medical Company Insight Go to article: SHL MedicalGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: CSafe GlobalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: CommentGo to article: Tapping into pharma’s growing opportunities in digital healthGo to article: Covid-19 Omicron boosters will reinvigorate injectables manufacturingGo to article: Implementation of electronic health records will improve the quality of careGo to article: Despite benefits, long-acting injectables remain underutilised for schizophreniaGo to article: FDA approves Coherus’ Cimerli for DME, with year-long interchangeability exclusivityGo to article: UK health data collaboration paves the way to study Long Covid symptomsGo to article: Molnar-Institute Company Insight Go to article: Molnar-InstituteGo to article: In DepthGo to article: A makeover for NICE: a new look for HTAs in the UK Go to article: No drugs for prions: investigating new approaches to alleviate therapeutic scarcGo to article: Getting smart with digital pillsGo to article: Do generics producers have what it takes to tackle complex and specialty drugs?Go to article: Decentralised paediatric clinical trials trending up but study execution criticaGo to article: CMO Moves: Regulatory catalysts for drug manufacturing—August Go to article: Biolife SolutionsGo to article: In DataGo to article: Healthtech deals decreased significantly in the pharma industry in H1 2022Go to article: North America is seeing a hiring boom in pharmaceutical industry machine learninGo to article: Artificial intelligence mentions decrease in pharma filings in Q2 of 2022Go to article: Digital media hiring levels in the pharmaceutical industry rose in June 2022Go to article: EventsGo to article: Next issue